Clinical trial

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

NCT01506609

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Veliparib Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatinView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Temozolomide Normalized identity: temozolomideView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Paclitaxel Normalized identity: paclitaxelView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-01-23

PhasePHASE2

Conditions

Metastatic Breast Cancerunresolved

Interventions

PlaceboDRUG

VeliparibDRUG

CarboplatinDRUG · verified · RxNorm: carboplatin

TemozolomideDRUG · verified · RxNorm: temozolomide

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Sponsors & collaborators

AbbVielead sponsor

Mapped research locations

ChicagoIllinois, United States3 Saint PetersburgRussia3 MemphisTennessee, United States3 New YorkNew York, United States2 BostonMassachusetts, United States2 MadridSpain2 BarcelonaSpain2 PittsburghPennsylvania, United States2 MontrealQuebec, Canada2 BucharestRomania2 PoznanPoland2 JerusalemIsrael2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01506609 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.